Have you been paying attention to shares of Artivion (AORT) ? Shares have been on the move with the stock up 9.6% over the past month. The stock hit a new 52-week high of $21.82 in the previous session. Artivion has gained 18.3% since the start of the year compared to the 8.2% move for the Zacks Medical sector and the 9.4% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings ...

As many know, small-caps’ volatile nature can sometimes turn investors away. However, many small-cap stocks turn out to be big winners in the long run, and they typically have fewer eyes on them, providing investors an opportunity to get in "early" before the crowd. For those seeking exposure to small-caps, three stocks – EZCORP (EZPW) , Artivion (AORT) , and QuickLogic (QUIK) – could all be considered. All three sport a favorable Zacks Rank, indicating optimism among analysts. Let’s take a closer look at e ...

The Medical Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. The industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on and so forth. The medical instruments space has been benefiting from the ongoing merger and acquisition trend. The smaller and m ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Artivion (AORT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. Artivion is a member of our Medical group, which includes 1066 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges t ...

ATLANTA, March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 13, 2023. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 59-2417093 (State or other jurisdiction of incorpo ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Artivion (AORT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year- to-date performance to find out. Artivion is one of 1067 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector R ...

Artivion股价表现 - Artivion (AORT)股价在过去一个月中表现强劲，上涨了15.9%[1] 盈利情况 - 公司在过去四个季度中均未错过盈利预期，最近一次财报显示，公司每股收益为0.11美元，超过了预期[2] - 预计本财年，Artivion每股盈利将达到0.26美元，营收为3.889亿美元，而下一财年预计每股盈利将达到0.58美元，营收为4.2705亿美元[3] 公司评分和股票展望 - 公司目前的价值评分为C，成长和动量评分分别为A和A，综合评分为B[4] - Artivion目前的股价较同行业平均值高出很多，但公司的Zacks Rank为1(强烈买入)，显示出有利的盈利预期修订[5] - 根据Zacks的建议，Artivion股票似乎符合投资标准，有望在短期内继续上涨[6]

Artivion (AORT) closed the last trading session at $18.70, gaining 6.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.44 indicates a 30.7% upside potential. The average comprises four short-term price targets ranging from a low of $22 to a high of $25.75, with a standard deviation of $1.66. While the lowest estimate indicates an increase of 17.7% from the current price level, ...

财务数据和关键指标变化 - 2023年第四季度收入为9370万美元,同比增长15% [11][12][30] - 2023年全年收入同比增长12%,超过目标 [11] - 2023年第四季度非GAAP调整后EBITDA增长40%至1530万美元 [14][30] - 2023年全年实现正自由现金流,这是公司的重要里程碑 [30] - 2024年预计收入增长8%-12%,调整后EBITDA增长26%-34% [38][39] 各条业务线数据和关键指标变化 - On-X业务收入增长19% [15][31] - 组织加工业务收入增长18% [16][31] - BioGlue业务收入增长11% [13][31] - 支架业务收入增长8% [17][31] 各个市场数据和关键指标变化 - 亚太和拉美地区收入同比增长19% [18][32] - 北美地区收入增长17%,欧洲地区增长10% [32] 公司战略和发展方向及行业竞争 - 公司正在建设一家全面的主动脉疾病公司,持续投资创新管线 [60][61] - AMDS技术在急性A型主动脉夹层中显示出72%的死亡率降低和52%的主要不良事件降低,是一项突破性技术 [56][57][58] - 公司正在开发第三代冻结大象干管技术ARCEVO,预计2027年左右获批 [72][73] - On-X机械主动脉瓣膜在欧洲的一项510例研究显示主要出血事件降低85% [52][78] 管理层对经营环境和未来前景的评论 - 公司对2024年的业务前景充满信心,将继续保持强劲的增长势头 [51][52] - 亚太和拉美地区将成为未来几年的重要增长动力 [18][52] - 公司的创新管线和资本结构为未来发展奠定了良好基础 [51][52] 问答环节重要的提问和回答 问题1 **John McAulay 提问** 对AMDS技术在欧洲的表现和未来在美国的机会有何看法 [55][56] **Pat Mackin 回答** AMDS技术在急性A型主动脉夹层中显示出72%的死亡率降低和52%的主要不良事件降低,是一项突破性技术,公司将积极推进美国市场的获批和商业化 [56][57][58] 问题2 **Mike Matson 提问** 对ARCEVO技术的时间进度有何预期 [72] **Pat Mackin 回答** 预计ARCEVO技术将在2027年左右获批上市 [72][73] 问题3 **Suraj Kalia 提问** 对AMDS在美国市场的机会空间有何看法 [78][79] **Pat Mackin 回答** AMDS在美国急性A型主动脉夹层市场的机会空间约为1.5亿美元,这是一项真正的生命救助技术,公司有信心推动其快速商业化 [78][79]